Bilateral Occipital Nerve Field Stimulation for the Treatment of dtCCH

Chronic Cluster Headache Clinical Trial

— BONS  

Official title:

Bilateral Occipital Nerve Field Stimulation for the Prophylactic Treatment of Difficult-to-treat Chronic Cluster Headache

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06124534
• Other study ID #: DOC-130
• Status: Recruiting
• Phase: N/A
• Start date: October 19, 2023
• Est. completion date: March 30, 2025

Study information

• Verified date: November 2023
• Source: Man and Science, SA
• Contact: Christelle Nguepi
• Phone: +33 679 673787
• Email: c.nguepi[@]manandscience.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the initial safety, tolerability, and effectiveness of the novel BliStim occipital nerve field stimulation therapy for the prevention of chronic cluster headaches. This is a prospective, first in human study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: March 30, 2025
• Est. primary completion date: November 21, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. ICHD-3 criteria for chronic cluster headache

2. Documented history of CCH since at least 2 years

3. Minimum mean attack frequency of 4 attacks per week

4. Age range: 18-70 years

5. Difficult-to-treat CCH with documented previous complete failure, insufficient efficacy, intolerance, or contra-indications to most preventive CH treatments among which are oral steroids or suboccipital infiltrations, verapamil, lithium carbonate and topiramate.

6. No preventive CH treatment or stable preventive CH medication for = 2 weeks before enrolment. Subject agrees not to change existing treatment during the whole duration of the trial.

7. Subject written informed consent provided before enrolment

8. Subject willing and capable of subjective evaluation and to fill in an electronic CH diary, to understand questionnaires, and to read, understand and sign the written informed consent form.

9. Subject willing and able to comply with study-related requirements, procedures, and visits.

Exclusion Criteria:

1. Other significant neurological, psychiatric, or disabling diseases which in the opinion of the investigator may interfere with the study.

2. History of epilepsy, current treatment of epilepsy

3. Documented history of cerebrovascular accident (CVA)

4. Subjects suffering from a substance use disorder, as defined by Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria. Recreational use of cannabis is allowed.

5. Subjects at high risk of suicide/suicidal ideation in the past one year assessed with the C-SSRS

6. Having another active implanted device such as a cardiac pacemaker, a spinal cord, peripheral nerve, sphenopalatine ganglion, or deep brain hypothalamic stimulator, and/or a drug delivery pump, etc.

7. Cranial botulinum toxin injections in the past 3 months before enrolment. Administration of the following treatments in the last month before enrolment: monoclonal antibodies blocking calcitonin gene-related peptide transmission, suboccipital infiltrations with steroids and/or local anaesthetics, oral steroids, radiofrequency procedure or infiltrations of the sphenopalatine ganglion, opioids WHO 3.

8. Medication overuse headache (ICHD 3 8.2)

9. Inability to fill out an electronic diary.

10. Previous surgery or trauma involving the cervical spine or the occipital bone

11. Coagulopathy or required anticoagulant medications that cannot be safely discontinued in the perioperative period.

12. Concurrent participation in another clinical study

13. Planned pregnancy, pregnancy, or breastfeeding.

Related Conditions & MeSH terms

• Chronic Cluster Headache
• Cluster Headache
• Headache

Intervention

Device:
• Neurostimulation of the Occipital Nerve Field
BliStim Neurostimulation system

Locations

Country	Name	City	State
Belgium	VITAZ Hospital	Sint-Niklaas

Sponsors (1)

Lead Sponsor	Collaborator
Man and Science, SA

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety Evaluation of the Device [Time Frame:12 weeks / 48 weeks]	The primary endpoint is safety and is assessed through the incidence of procedure related and/or device-related adverse events during the 12-weeks post implantation and the rate of all adverse events during the entire 48-week study period.	12-weeks post implantation and through study completion at 48 weeks